 Oragenics Inc NYSE: OGEN has extended a licensing and collaboration agreement with the National Research Council of Canada NRC to enable Oragenics to pursue an intranasal vaccine designed against omicron variant. The NRC cell expression technologies provide Oragenics with a platform to generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern. 